SEC Form 4 · accession 0001193125-26-330530
Kalaris Therapeutics, Inc. · KLRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Laurie Keating
Director
Period of report
Aug 1, 2026
Accepted (ET)
Aug 3, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001754068
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $3.51 | Aug 1, 2026 | A | 18,000 | A | — | Jul 31, 2036 | Common Stock | 18,000 | 18,000 | D |
Explanation of responses
- F1The option was granted on August 1, 2026. The shares underlying the option are scheduled to vest over three years in equal monthly installments from August 1, 2026 through August 1, 2029, subject to continuous service.